MENU

Completed Grants and Sponsored Research

Project Date: November 1, 2017 - February 28, 2019
Sponsoring Organization: Children's Oncology Group

Development of Liquid Biopsy Assays for Wilms Tumor

Description of Major Goals
The goal of this project is to develop a circulating tumor DNA assay that utilizes peripheral blood draws to quantify DNA released from the tumors into the blood stream as a surrogate for measuring tumor burden, treatment response, and monitoring for relapse in patients with Wims tumor.
Sponsor Grant ID: Basic Research Science Grant Project Date: January 01, 2017 - December 31, 2018
Sponsoring Organization: Pediatric Cancer Research Foundation

Development of Circulating Tumor DNA Assays for Translocation Positive Sarcomas

Description of Major Goals
The major goal of this project is to validate the measurement of circulating tumor DNA assays (also known as liquid biopsies) obtained from blood samples as a biomarker of poor outcome for patients with Ewing sarcoma. We believe the results of this study could radically change the way we treat patients with the most aggressive form of this disease.
Project Date: July 1, 2016 - June 30, 2018
Sponsoring Organization: Boston Children's Hospital Translational research Program

Development of Circulating Tumor DNA Assays for Ewing Sarcomas

Description of Major Goals
In this proposal, we aim to validate a new assay that detects tumor DNA from peripheral blood draws as a surrogate for tumor burden.
Sponsor Grant ID: Scholar Award Project Date: July 1, 2013 - June 30, 2018
Sponsoring Organization: St. Baldrick's Foundation

Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma

Description of Major Goals
The major goals of this project are to perform preclinical testing of FAK inhibition using in vivo models of tumor progression and metastasis, to determine effective combinations of therapy with FAK inhibition in the treatment of Ewing sarcoma, and to determine which integrins are necessary for growth, transformation, and FAK activation in Ewing sarcoma.
Project Date: July 01, 2015 - June 30, 2017
Sponsoring Organization: Children's Oncology Group

Prognostic significance of STAG2 loss and TP53 mutations in Ewing sarcoma

Description of Major Goals
The aims of this project are: (1) Does STAG2 and TP53 immunohistochemical staining successfully identify tumors with deleterious mutations in these genes? (2) Is STAG2 loss, alone or in combination with TP53 alteration, predictive of poor outcome inpatients with localized disease? (3) Does STAG2 loss occur more commonly in patients who present with metastatic disease?
Sponsor Grant ID: Grant Project Date: May 1, 2016 - April 30, 2017
Sponsoring Organization: Go4TheGoal Foundation

Development of Circulating Tumor DNA Assays for Translocation Positive Sarcomas

Description of Major Goals
The major goals of this project are to validate TranSS-Seq assay for detection of targeted sarcoma translocations in patient plasma; to correlate tumor-derived cfDNA level at diagnosis with outcome in cases of translocation-positive pediatric sarcomas; to correlate tumor-derived cfDNA levels over time with clinical course in translocation­positive pediatric sarcomas.
Sponsor Grant ID: Research Grant Project Date: January 01, 2016 - December 31, 2016
Sponsoring Organization: Pediatric Cancer Research Foundation

Bridging the gap between target discovery and clinical trials in pediatric Ewing sarcoma

Description of Major Goals
The major goals of this project are to perform the preclinical studies necessary to validate the use of FAK inhibition as a therapeutic approach to prevent disease progression and metastasis. Our approach will include testing the use of anti-Ewing chemotherapy and other targeted agents in combination with FAK inhibition to identify the most promising combinations. We also will utilize a genetic screening approach to find new therapeutic targets that may cooperate with FAK activity in Ewing sarcoma.
Project Date: January 1, 2014 - December 31, 2015
Sponsoring Organization: Pediatric Cancer Research Foundation

Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma

Description of Major Goals
The major goals of this project are to complete the necessary preclinical studies to bring a FAK inhibitor to clinical trials for children with Ewing sarcoma; to determine if there is a role for this treatment approach in the prevention of metastatic disease; to nominate synergistic therapeutic combinations for future trials, and to identify additional adhesion molecules that play a role in the pathogenesis of Ewing sarcoma and activate FAK.
Project Date: July 1, 2013 - June 30, 2015
Sponsoring Organization: Bear Necessities Pediatric Cancer Foundation

Targeting FAK and integrin signaling in preclinical models of Ewing sarcoma

Description of Major Goals
The major goals of this project are to perform preclinical testing of FAK inhibition using in vivo models of tumor progression and metastasis, to determine effective combinations of therapy with FAK inhibition in the treatment of Ewing sarcoma, and to determine which integrins are necessary for growth, transformation, and FAK activation in Ewing sarcoma.